adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. OIC-related tickers: ( SLXP -0.6% )( PGNX +1.9% )( NKTR -0.5% )( AZN -2% )( CBST +0.1% )( SGYP +0.7% ) Post your comment!
FDA's approval of Relistor (methylnaltrexone bromide) for OIC triggers a $40M milestone payment to Progenics Pharmaceuticals ( PGNX -5.3% ) from worldwide collaboration partner Salix Pharmaceuticals ( SLXP -3.6% ). Under the terms
docs Prostate cancer therapy-related tickers:( TKAI -2.1% )( MDVN +1.2% )( NYMX +4.8% )( EXEL -0.3% )( PGNX +2.8% )( MRK +1.8% )( ADXS +2.7% )( EBS +1.8% )( EDAP +3% )( ISIS +2.1% )( NVGN )( DNDN +0.7
By AvetCap : Since PGNX is a fairly well-known company among ..... into the sources of upside. Valuation : PGNX is trading at an enterprise value of ..... brings the valuation down to $ 213mm . PGNX also stands to receive a $50mm milestone
chronic non-cancer pain." Salix (NASDAQ: SLXP ) will sell Relistor under a license from developer Progenics (NASDAQ: PGNX ). Many expected FDA approval to arrive following a favorable July ruling . PGNX +3.4% AH. Post your comment!
regulatory and launch milestones, tiered sales-related milestones up to $375M and double-digit royalties on net global sales. Related tickers: (NASDAQ: PGNX ) (NASDAQ: CBST ) (NASDAQ: SLXP ) (NASDAQ: SGYP ) Post your comment!
treatment of opioid-induced constipation (OIC). Salix ( SLXP +5% ) successfully appealed the FDA's CRL for the indication in July. ( PGNX +0.6% )( NKTR +1.8% )( AZN -4% )( CBST +0.6% )( SGYP +3.1% ) Post your comment!
International Symposium of Pheochromocytoma and Paraganglioma in Kyoto, Japan on data from a Phase 2 trial of Progenics Pharmaceuticals ' ( PGNX -3.1% ) Azedra (Ultratrace Iobenguane I-131). Azedra is the company's radio-therapeutic candidate
induced constipation who take opioids for the management of chronic non-cancer pain. Movantik is distributed by AstraZeneca ( AZN -0.9% ). Related tickers: ( PGNX -0.2% ) ( SLXP +3.7% ) ( CBST +0.1% ) Post your comment!
Progenics Pharmaceuticals ( PGNX -2.4% ) settles its arbitration with Ono Pharmaceutical Company over Ono's rights to subcutaneous Relistor in Japan and its